What's New

2024 Dallas Marathon: December 14-15

Please support our team as we take on the 2024 Dallas Marathon on December 14-15 and raise money for AFTD!

Read More about 2024 Dallas Marathon: December 14-15

2024 New York City Marathon: November 3

Please support our team as we take on the 2024 TCS New York City Marathon on November 3 and raise money for AFTD!

Read More about 2024 New York City Marathon: November 3

Transposon Announces Results from Phase 2 PSP Trial, Interim Results for Phase 2 FTD/ALS Trial

The biotechnology company Transposon Therapeutics on February 12 released final results for its phase 2 clinical trial focusing on progressive supranuclear palsy (PSP) and interim results for its phase 2…

Read More about Transposon Announces Results from Phase 2 PSP Trial, Interim Results for Phase 2 FTD/ALS Trial

2024 Philadelphia Marathon: November 23-24

Join the AFTD-Team at the 2024 Philadelphia Marathon, as we bring greater FTD awareness to the surrounding Philadelphia area and raise funds to help people affected by FTD. The AFTD-Team…

Read More about 2024 Philadelphia Marathon: November 23-24

2024 Colfax Marathon: May 18-19

Join select AFTD staff and members of the local community at the 2024 Colfax Marathon, as we bring greater FTD awareness to the surrounding Denver area and raise funds to…

Read More about 2024 Colfax Marathon: May 18-19

2024 Los Angeles Marathon: March 17

Join select AFTD staff and members of the local community as we bring greater FTD awareness to the surrounding Los Angeles area and raise funds to help people affected by…

Read More about 2024 Los Angeles Marathon: March 17

2024 Austin Marathon: February 18

Join select AFTD staff and members of the local community at the 2024 Austin Marathon as we bring greater FTD awareness to the surrounding Austin area and raise funds to…

Read More about 2024 Austin Marathon: February 18

Treat FTD Fund Grant Recipient Discusses FTD-GRN Gene Therapy in Newspaper Interview

Simon Ducharme, MD, MSc, FRCPC, of McGill University, a recent recipient of a grant through the Treat FTD Fund, discussed an experimental gene therapy for FTD-GRN in a December interview…

Read More about Treat FTD Fund Grant Recipient Discusses FTD-GRN Gene Therapy in Newspaper Interview

Viewpoints of FTD: Addressing Barriers to Diagnosis, FTD Care, and Research Participation Faced by Black/African Americans

In 2011, researchers estimated there to be 50,000-60,000 cases of FTD in the United States. Today, however, researchers believe this figure to be an undercount. One reason for this is…

Read More about Viewpoints of FTD: Addressing Barriers to Diagnosis, FTD Care, and Research Participation Faced by Black/African Americans

FDA Grants Breakthrough Therapy Designation to Experimental FTD Therapy

The U.S. Food and Drug Administration (FDA) has granted a “breakthrough therapy designation” to latozinemab, an experimental treatment for FTD caused by a GRN genetic mutation. The drug is being…

Read More about FDA Grants Breakthrough Therapy Designation to Experimental FTD Therapy